Abstract. The limitations of current therapies for the treatment of iron overload or radioisotope contamination have stimulated efforts to develop new orally bioavailable iron and actinide chelators. Siderophore-inspired tetradentate, hexadentate and octadentate terephthalamidate and hydroxypyridonate ligands were evaluated in vivo as selective and efficacious iron or actinide chelating agents, with several metal loading and ligand assessment procedures, using 59 Fe, 238 Pu, and 241 Am as radioactive tracers. The compounds presented in this study were compared to commercially available therapeutic sequestering agents (desferrioxamine for iron and diethylenetriaminepentaacetic acid for actinides) and are unrivaled in terms of affinity, selectivity and decorporation efficacy, which attests to the fact that high metal affinity may overcome the low bioavailability properties commonly associated to multidenticity.
INTRODUCTION
Chelation therapy is the only therapeutic approach that leads to enhanced metal excretion in patients with iron-overload conditions such as β-thalassemia or in patients contaminated with harmful internalized radionuclides such as actinides (1) (2) (3) (4) . While continuous infusions of the natural siderophore Desferrioxamine (DFO, Figure 1 ) have significantly raised the life expectancy of patients with transfusional iron overload over the last four decades, the leading cause of death in thalassemia major remains cardiac disease from myocardial iron deposition and the administration regimen of DFO often results in poor compliance (5) . Similarly, diethylenetriaminepentaacetic acid (DTPA, administered as CaNa 3 -or ZnNa 3 -DTPA, Figure 2 ), the only approved actinide decorporation agent (2, 6) , can reduce the acute radiation damage, late radiation effects and chemical toxicity caused by internalized actinides. However, DTPA is not active when administered orally and is not suitable for the simultaneous long-term treatment of a large population. Extensive research efforts have therefore been dedicated to the development of low-cost orally active iron and actinide chelators with high efficacy and low toxicity profiles.
The fundamental hypothesis underlying our approach to the development of new chelators is that thermodynamic stability of the corresponding metal complexes is a necessary requirement.
The relative complexing abilities of iron chelating agents that vary in denticity (degree to which they individually satisfy the six coordination requirements of iron) are shown in Figure 1 . While DFO remains the predominantly used iron chelator, its thermodynamic stability is not matched by oral activity (5) , In contrast, the bidentate chelator Deferiprone (L1, Figure 1 ) is relatively inexpensive and orally active (4, 7, 8) . However, L1 has a very rapid drop-off in stability with concentration ( Figure 1 ), which requires usage at a high dose and thus can be related to serious toxicity problems. The tridentate chelator Deferasirox (ICL670A), recently introduced by Novartis (9), has moderate stability at low concentrations, forming a two to one complex with ferric ion. It is orally effective but has also been associated with a number of toxicity problems and is costly (4, 8, 10) . Our hypothesis remains that any tridentate or bidentate ligand will be problematic because of the relatively high concentrations required by second-or third-order dependence on ligand concentration for a fully formed ferric complex. Incompletely complexed iron, which may be Fenton-reactive, may also contribute to toxic side effects by hydroxyl radical catalyzed oxidative injury.
[Figure 1]
Similarly, multidentate chelators will fulfill the high coordination requirements of actinides such as Pu(IV) and Am(III), and will form the most stable complexes. Therefore, our research is focused on the development of high-denticity ligands (hexadentate and tetradentate for iron; octadentate and tetradentate for actinides) as new therapeutic chelators. Because high-denticity ligands are inherently large molecules, few multidentate compounds have been designed and envisaged as potential orally active chelators (11) (12) (13) . However, thermodynamic complex stability, fast kinetics of complexation, lipophilicity and therapeutic index are other major parameters that determine the efficacy of a ligand when given orally (14) . Examples of prospective orally active therapeutics with large molecular sizes are presented herein.
All ligands include two, three, or four bidentate metal-binding groups, linked to polyamine scaffolds through amide functionalities, to form tetradentate, hexadentate or octadentate structures, respectively. Based on previous thermodynamic and biological studies, the 2,3-dihydroxyterephthalamide (TAM) metal-binding moiety was used in ligands targeting iron (15, 16) , while 1,2-hydroxypyridinone (1,2-HOPO) and methyl-3,2-hydroxypyridinone (Me-3,2-5 HOPO) units were incorporated into ligands targeting actinides (2, 6) . In this work, the effect of denticity on iron removal efficacy was investigated using three TAM-based iron chelators: the linear tetradentate ligand 5-LIO(TAMmeg), the linear hexadentate ligand 5-LIO 2 (TAM)(TAMmeg) 2 , and the tripodal hexadentate ligand TREN(TAMmeg) (Figure 1 ). In parallel, actinide removal studies performed with the tetradentate ligand 5-LIO(Me-3,2-HOPO) and the octadentate structure 3,4,3-LI(1,2-HOPO) ( Figure 2 ) were used to compare the efficacy of these large molecules when administered by injection or orally.
[Figure 2] MATERIALS AND METHODS
General. All chemicals were obtained from commercial suppliers and were used as received. LIO(Me-3,2-HOPO)) was contained in 0.5 mL of 0.14 M NaCl, the pH being adjusted to 7.4-8.4
with 1 N NaOH.
In Vivo Metal Removal Studies. The animals used were young adult female Swiss-Webster mice (87 ± 9 days old, 34 ± 2 g). Gross body and tissue compositions, plasma, extracellular fluid, and red cell volumes of the whole body, major tissues and organs of these mice (intact or bled 25
to 40% of their total blood volume) have been determined (20) . All experiments using 59 Fe, 238 Pu or 241 Am tracers were managed as metabolic balance studies, in which blood, all tissues, and excreta were analyzed for the appropriate tracer. The methods of sampling, sample preparation and radioanalysis have been described in details previously (21, 22) . Those methods provide quantitative measurements of the radioactivity in the biological samples, and material recoveries are about 95%, on average, of the amount injected. Under isoflurane anesthesia, groups of five mice were injected in a lateral tail vein with 0.2 mL metal tracer doses. Ligands were administered at 30 min or 1 h after the metal, for iron or actinide removal studies, respectively, by intraperitoneal (ip) injection to normally fed mice or orally (gastric intubation) to mice that had been fasted for 16 h. Each 5-mouse group was housed together in a plastic stock cage lined with a 0.5 cm layer of highly absorbent low-ash pelleted cellulose bedding (ALPHA-dri  ) for separation of urine and feces. All mice were given water and food ab libitum (for fasted mice,
food became available at 4 h after the metal injection), and were euthanized by cervical dislocation at 24 h after the metal injection. Samples included whole blood, plasma, liver, kidneys, spleen, gastrointestinal (GI) tract plus contents (divided at the ileocecal junction into upper and lower GI tract), residual carcass, urine (sorbed to the cellulose bedding) and passed feces. Samples were dried at 100 °C and dry ashed at 575 °C. The ashed samples were dissolved in dilute HNO 3 . The blood, plasma, and small tissue samples, which were dried, ashed and dissolved in their glass counting vials, and weight aliquots of the dissolved large samples (bulk soft tissue, skeleton, urine, feces) were mixed with Ultimagold ® for detection of the radiotracers by scintillation counting. Details of autopsy procedures, tissue and excreta collection and processing, as well as radioactivity measurements (liquid scintillation counting, Packard TriCarb model B4430) and methods of data reduction have been previously reported (21, 22) . (Tables 2 and 3) , and other dosages previously reported (19) . The 24-h actinide excretion promoted by these ligands in this protocol is illustrated in Figures 4 and 5 . At all concentrations tested, both experimental ligands promoted significantly more fecal and total actinide (for both 238 Pu and 241 Am) excretion than CaNa 3 -DTPA and the controls, and markedly reduced actinide content in the liver, kidneys, soft tissues and whole body as compared to controls. In addition, the actinide content in the liver and whole body of mice treated with the HOPO-containing ligands was considerably lower than that in mice treated with CaNa 3 -DTPA. In contrary to [ Tables 2 and 3 5-LIO(Me-3,2-HOPO) determined previously (19) and shown here for comparison purposes. c Carcass is skeleton, blood sample, and all soft tissue except liver, kidneys and GI tract (full).
RESULTS AND DISCUSSION

Efficacy of TAM-Containing Ligands for Promoting in vivo
d Mean is significantly less than for the control mice (t-test, p ≤ 0.01 (27) ).
e Mean is significantly less than for mice similarly treated with DFO (t-test, p ≤ 0.01 (27) c Mean is significantly less than for the similarly treated control mice (t-test, p ≤ 0.01 (27) ).
d Mean is significantly less than for mice similarly treated with CaNa 3 -DTPA (t-test, p ≤ 0.01 (27) ).
e Data previously reported and shown here for comparison purposes (19) .
